Tresiba Hair and Skin Changes: What the Clinical Evidence Actually Shows

What Skin Reactions Does Tresiba Cause at the Injection Site?

Injection-site reactions are the most consistently documented skin effects of insulin degludec. These include redness, swelling, itching, and pain at the injection site. Most reactions are mild, transient, and resolve without treatment. The FDA prescribing information for Tresiba lists injection-site reactions among adverse reactions occurring in clinical trials, though rates were low compared with placebo-controlled comparators.

Lipohypertrophy: The Most Clinically Significant Local Effect

Lipohypertrophy, the accumulation of fatty tissue at repeated injection sites, is the skin complication with the greatest clinical consequence for any insulin user, including those on degludec. A 2016 cross-sectional study published in Diabetes Therapy (N=225) found lipohypertrophy in 49.1% of insulin-using patients, with incorrect rotation technique as the dominant risk factor. Injecting into a hypertrophic area slows insulin absorption unpredictably, contributing to erratic glycemic control.

Degludec's ultra-long duration of action (approximately 42 hours at steady state) means that absorption variability caused by lipohypertrophy may persist longer than with shorter-acting insulins. The FDA label for Tresiba notes that lipodystrophy and localized cutaneous amyloidosis have been reported, and that injecting into such areas may lead to unpredictable insulin absorption and worsening glycemic control.

Lipoatrophy: Less Common but Harder to Reverse

Lipoatrophy, loss of subcutaneous fat at injection sites, is less frequent than lipohypertrophy but more disfiguring and slower to resolve. Its pathophysiology is thought to involve immune-mediated inflammation against insulin or excipients in the formulation. A 2021 case series in Diabetes Care described lipoatrophy persisting for months after switching insulins, underscoring that resolution is not guaranteed by changing formulations. No degludec-specific incidence data are available in the DEVOTE trial report because dermatologic outcomes were not a pre-specified endpoint.

Localized Cutaneous Amyloidosis

A specific, underrecognized injection-site complication is cutaneous amyloidosis, in which amyloid deposits form in the dermis at chronic injection sites. A 2017 FDA Drug Safety Communication warned prescribers about this risk across all insulin products, including degludec. The FDA noted that injecting into areas with amyloidosis may cause unpredictable absorption and urged site rotation as a preventive measure. Clinically, affected skin may appear firm, slightly discolored, or peau d'orange in texture.

Does Tresiba Cause Hair Loss?

Hair loss is not listed in the FDA prescribing information for insulin degludec. No phase III trial, including DEVOTE, identified alopecia as a treatment-emergent adverse event at a frequency that required label inclusion.

Post-Marketing Reports and MedWatch Data

Post-marketing surveillance captures signals that clinical trials may miss due to sample size or duration. The FDA Adverse Event Reporting System (FAERS) database does contain a small number of alopecia reports associated with insulin degludec, but causality assessment is inherently limited in spontaneous reporting systems. Confounders are abundant: patients with type 1 or type 2 diabetes have elevated background rates of alopecia areata and telogen effluvium compared with the general population independent of any specific insulin. A 2019 population-based study in JAMA Dermatology found that individuals with type 1 diabetes carry a significantly higher lifetime risk of alopecia areata, driven by shared autoimmune mechanisms rather than insulin therapy per se.

The Glycemic Control Hypothesis

Poorly controlled diabetes itself can cause telogen effluvium, a diffuse hair-shedding pattern triggered by physiologic stress. When patients switch to degludec and achieve tighter control, any concurrent hair shedding may be attributed to the drug rather than the preceding period of metabolic stress. ADA Standards of Care 2024 acknowledge that optimizing glycemic control reduces complications across multiple organ systems, including skin and hair follicle health, which depends on adequate microvascular perfusion.

Clinically, a hair-shedding event occurring within three months of any insulin initiation or dose change warrants a dermatology referral and thyroid function testing before attributing the finding to degludec.

Allergic Skin Reactions and Hypersensitivity

Systemic hypersensitivity reactions to insulin, though uncommon with modern analogs, can manifest as generalized urticaria, pruritus, and angioedema. Degludec, like all insulins, carries this risk. The Tresiba prescribing information states that severe, life-threatening generalized allergy including anaphylaxis may occur and should be treated immediately, with discontinuation of the drug.

Distinguishing Local From Systemic Reactions

Local reactions at the injection site (redness, wheal, flare) typically resolve within 30 to 60 minutes and do not require drug discontinuation. Systemic reactions involve skin beyond the injection site, respiratory symptoms, or hemodynamic instability. That distinction drives management: local reactions prompt technique review and antihistamine use, while systemic reactions require epinephrine and urgent evaluation.

A 2020 review in the Journal of Allergy and Clinical Immunology described graded desensitization protocols for patients with confirmed insulin allergy who have no viable alternative, though this scenario is rare with the current breadth of available formulations.

Excipient Sensitivity

Degludec's formulation contains zinc and glycerol among its excipients. The full ingredient list is detailed in the FDA label. Patients with documented metal sensitivities should discuss this with their prescriber, though zinc-induced contact dermatitis from subcutaneous insulin injection is an extraordinarily rare clinical event.

Cardiovascular Safety Trial: DEVOTE and What It Did (and Did Not) Measure for Skin

DEVOTE was a randomized, double-blind, treat-to-target cardiovascular outcomes trial comparing insulin degludec with insulin glargine U-100 in 7,637 adults with type 2 diabetes at high cardiovascular risk. Published in the New England Journal of Medicine in 2017, DEVOTE demonstrated non-inferiority for major adverse cardiovascular events (MACE) and a statistically significant 53% reduction in severe nocturnal hypoglycemia with degludec (rate ratio 0.47, 95% CI 0.31 to 0.73, P<0.001).

DEVOTE did not include skin or hair endpoints as pre-specified outcomes. The trial's primary focus on cardiovascular safety means its adverse event tables capture events that met a threshold for reporting, and low-incidence dermatologic findings would not appear unless they rose to serious adverse event status. Clinicians should not interpret the absence of skin data in DEVOTE as evidence that skin reactions do not occur.

What the BEGIN Trial Program Adds

The BEGIN trial program, a series of phase III trials evaluating degludec across type 1 and type 2 diabetes populations, reported injection-site reactions at rates comparable to glargine comparators, generally under 3% across arms. BEGIN BASAL-BOLUS Type 1 (N=629) found no significant difference in local tolerability between degludec and glargine U-100. No alopecia or systemic skin events were reported at a frequency requiring specific label language in the phase III program.

Skin Care and Injection Technique Recommendations

The following clinical decision framework draws on ADA guidance, FDA labeling, and peer-reviewed injection technique literature to help clinicians and patients minimize dermatologic complications with degludec.

Site Selection and Rotation

The abdomen, thighs, upper arms, and buttocks are all approved injection sites for degludec. ADA Standards of Care 2024 recommend systematic rotation within each site, moving at least one to two centimeters from the prior injection point, rather than random rotation. A structured rotation map, for example, dividing the abdomen into quadrants and rotating clockwise, reduces cumulative trauma to any single area.

Patients should palpate each site before injection. Any firmness, lumps, or skin thickening should prompt immediate site change and a clinical assessment for lipohypertrophy or cutaneous amyloidosis.

Needle Length and Gauge

For most adults, a 4 mm pen needle is sufficient for subcutaneous delivery regardless of BMI, according to a 2016 consensus statement from the Forum for Injection Technique. Longer needles increase the risk of intramuscular injection, which accelerates degludec absorption and raises hypoglycemia risk, and also increases bruising and local tissue trauma.

Skin Preparation and Post-Injection Care

Alcohol swabbing is standard but should be allowed to dry completely before injection to avoid stinging and potential lipid disruption in the skin. After injection, gentle pressure without rubbing minimizes bruising. Massaging the site is not recommended because it may alter absorption kinetics for degludec, whose ultra-long profile depends on a stable subcutaneous depot forming from its soluble multi-hexamer configuration.

When to Refer to Dermatology

Clinicians should refer patients to dermatology when:

• Lipohypertrophy does not improve after three months of correct rotation technique.
• Lipoatrophy is progressive or causes cosmetic distress.
• Localized skin changes are firm, discolored, or have an unusual texture suggesting cutaneous amyloidosis.
• Hair shedding exceeds 100 hairs per day for more than eight weeks and is temporally associated with insulin initiation.

Degludec-Specific Pharmacology and Why It Matters for Skin

Insulin degludec forms soluble multi-hexamers after subcutaneous injection, which slowly dissociate into monomers for absorption. This mechanism produces an ultra-long, flat pharmacokinetic profile with a half-life of approximately 25 hours and a duration exceeding 42 hours. The pharmacology was characterized in a 2012 study in Diabetologia and is what allows once-daily dosing with flexible timing.

From a skin perspective, this depot mechanism means that any disruption to the subcutaneous environment at the injection site, including lipohypertrophy, cutaneous amyloidosis, or scar tissue from repeated injections, has a proportionally larger effect on pharmacokinetics than it would for a shorter-acting insulin. A 2015 study in Diabetes, Obesity and Metabolism confirmed that injecting degludec into lipohypertrophic tissue produced significantly higher intra-individual pharmacokinetic variability compared with healthy tissue, with a coefficient of variation for insulin exposure nearly doubling.

Steady-State Considerations

Degludec reaches steady state after three days of once-daily dosing. During this period, patients may notice injection sites that are mildly more reactive as the depot concentration builds. This is a physiologic phenomenon, not an allergic one. Educating patients about this transition period reduces unnecessary alarm and abandonment of a regimen that may be optimal for their glycemic profile.

Glycemic Control, Skin Health, and the Diabetes Connection

Suboptimal glycemic control independently damages skin through several pathways. Advanced glycation end-products (AGEs) accumulate in collagen, making skin stiffer and less resilient. A study in Diabetes Care measured skin autofluorescence as a surrogate for AGE accumulation and found that values correlated with HbA1c over time. Peripheral neuropathy reduces sweat gland function, leading to dry, cracked skin that is more susceptible to infection. Microvascular disease impairs wound healing.

By achieving superior glycemic control compared with some alternatives, DEVOTE showed degludec's HbA1c reductions were non-inferior to glargine at 57 weeks, degludec may indirectly support better skin health in patients who were previously poorly controlled. This is a class effect shared with all effective basal insulins, not a unique property of degludec.

Diabetic Dermopathy and Its Distinction From Drug Effects

Diabetic dermopathy (shin spots) affects up to 40% of people with longstanding diabetes, producing round, scaly, light-brown patches on the shins. A review in the International Journal of Dermatology traced its pathogenesis to microangiopathy and trauma rather than any specific medication. Patients sometimes attribute these lesions to insulin therapy. Distinguishing diabetic dermopathy from injection-site reactions requires noting the distribution: dermopathy appears on the shins, not injection sites, and does not resolve with drug changes.

Monitoring Protocol for Patients on Degludec

A reasonable monitoring protocol for skin and hair in patients starting degludec includes:

• Baseline: Document injection sites, note any pre-existing lipodystrophy, photograph areas if abnormal.
• At 3 months: Palpate all injection sites during clinic visit. Review rotation technique with a diabetes care and education specialist.
• At 6 months: Re-examine if any baseline abnormalities were present. Order thyroid function tests if hair shedding has been reported.
• Annually: Full skin assessment as part of the ADA comprehensive diabetes evaluation, including inspection for dermopathy, necrobiosis lipoidica, and injection-site changes.

The ADA Standards of Care 2024 state: "Comprehensive foot and skin examinations should be performed at each visit for patients at high risk and at least annually for all patients with diabetes."